The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists

Area of Science:

• Pharmacology
• Adrenergic Receptor Research
• Lipid Metabolism

Background:

• Beta-adrenoceptors mediate various physiological responses, including lipolysis.
• Current classification distinguishes between beta-1 and beta-2 adrenoceptors based on tissue distribution and function.
• The specific adrenoceptor subtype responsible for lipolysis in white adipocytes requires further characterization.

Purpose of the Study:

• To characterize the adrenoceptor subtype involved in rat white adipocyte lipolysis.
• To compare the activity of known and novel beta-adrenoceptor agonists across different tissues.
• To investigate the binding characteristics of beta-adrenoceptor antagonists on adipocytes.

Main Methods:

• Determination of EC50 and relative intrinsic activity for several beta-adrenoceptor agonists (isoprenaline, fenoterol, salbutamol, prenalterol, BRL 28410, BRL 35113, BRL 35135) on rat white adipocyte lipolysis, rat atria, rat uterus, and guinea-pig trachea.
• Assessment of pA2 values for beta-adrenoceptor antagonists (propranolol, practolol, ICI 118,551, sotalol) on adipocytes, atria, and trachea.

Main Results:

• Novel agonists BRL 28410, BRL 35113, and BRL 35135 demonstrated selectivity for the adipocyte lipolytic response.
• Existing agonists showed selectivity for other tissues: fenoterol and salbutamol for trachea/uterus, prenalterol for atria.
• Antagonist studies revealed distinct binding affinities on adipocytes compared to atria and trachea, indicating a non-canonical receptor profile.

Conclusions:

• The rat white adipocyte lipolytic receptor exhibits pharmacological properties distinct from classical beta-1 and beta-2 adrenoceptors.
• Both agonist and antagonist data challenge the current beta-adrenoceptor classification system regarding adipocyte lipolysis.
• Further research is warranted to define the unique characteristics of the adipocyte beta-adrenoceptor.